Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.69
-$0.014-0.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.17% | -73.91% | -0.62% | -43.87% | -45.38% |
| Total Depreciation and Amortization | 1,275.00% | 0.00% | -20.00% | -16.67% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.09% | 154.48% | 55.39% | 18.70% | 57.71% |
| Change in Net Operating Assets | -183.14% | 1,842.80% | -113.98% | 299.32% | -197.22% |
| Cash from Operations | -159.61% | 18.65% | -43.94% | 16.73% | -164.46% |
| Capital Expenditure | 49.23% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 49.23% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.15% | 136.64% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.22% | -- | -- | -- | -- |
| Cash from Financing | -73.56% | 387.68% | -- | -100.00% | 102.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.43% | 939.74% | 55.97% | 16.71% | -159.74% |